The commonality of Alzheimer's disease (AD) in the elderly suggests connections between aging and AD biology. APOE biology is also tied to AD.
Objective
We sought to link three aging hallmarks (loss of proteostasis, mitochondrial dysfunction, deregulated nutrient sensing) to APOE biology.
Methods
We altered SH-SY5Y cell proteostasis directly via heat shock, integrated stress response inhibition (ISRIB), or autophagy inhibition (chloroquine), and indirectly by perturbing mitochondria (mtDNA depletion; oligomycin). We also exposed induced pluripotent stem cell-derived neurons to ISRIB and chloroquine. Conversely, we mitigated protein stress with rapamycin. We assessed intervention impact on APOE expression.
Results
Increasing protein stress elevated and decreasing protein stress lowered APOE expression. In SH-SY5Y cells rapamycin blocked oligomycin-induced mTOR 2448 phosphorylation, Akt 473 phosphorylation, and APOE expression. In chloroquine-treated neurons rapamycin reduced mTOR phosphorylation and APOE expression.
Discussion
Protein stress initiates APOE expression and facilitates mitochondrial dysfunction's impact on APOE by engaging the mTOR pathway. Our findings link aging and AD biology.
SwerdlowRH. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?Neurobiol Aging2007; 28: 1465–1480.
2.
RahimiJKovacsGG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther2014; 6: 82.
3.
JansenWJOssenkoppeleRKnolDL, et al.Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA2015; 313: 1924–1938.
4.
López-OtínCBlascoMAPartridgeL, et al.Hallmarks of aging: an expanding universe. Cell2023; 186: 243–278.
5.
WodrichAPKScottAWShuklaAK, et al.The unfolded protein responses in health, aging, and neurodegeneration: recent advances and future considerations. Front Mol Neurosci2022; 15: 831116.
6.
KalininAZubkovaEMenshikovM. Integrated stress response (iSR) pathway: unraveling its role in cellular senescence. Int J Mol Sci2023; 24: 17423.
7.
WallaceDC. Mitochondrial genetics: a paradigm for aging and degenerative diseases?Science1992; 256: 628–632.
WangSLongHHouL, et al.The mitophagy pathway and its implications in human diseases. Signal Transduct Target Ther2023; 8: 304.
11.
SwerdlowRH. The Alzheimer's disease mitochondrial cascade hypothesis: a current overview. J Alzheimers Dis2023; 92: 751–768.
12.
OliverDMAReddyPH. Molecular basis of Alzheimer's disease: focus on mitochondria. J Alzheimers Dis2019; 72: S95–s116.
13.
WangWZhaoFMaX, et al.Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener2020; 15: 30.
14.
SwerdlowRH. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Signal2012; 16: 1434–1455.
ChandelNS. Signaling and metabolism. Cold Spring Harb Perspect Biol2021; 13: a040600.
17.
HuangJManningBD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans2009; 37: 217–222.
18.
PerluigiMDi DomenicoFBaroneE, et al.mTOR in Alzheimer disease and its earlier stages: links to oxidative damage in the progression of this dementing disorder. Free Radic Biol Med2021; 169: 382–396.
19.
CorderEHSaundersAMStrittmatterWJ, et al.Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science1993; 261: 921–923.
20.
GaratacheaNEmanueleECaleroM, et al.Apoe gene and exceptional longevity: insights from three independent cohorts. Exp Gerontol2014; 53: 16–23.
21.
MahleyRWHuangY. Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron2012; 76: 871–885.
22.
HoltzmanDMHerzJBuG. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med2012; 2: a006312.
23.
GabrielliAPWeidlingIRanjanA, et al.Mitochondria profoundly influence apolipoprotein E biology. J Alzheimers Dis2023; 92: 591–604.
24.
WynneMEOgunbonaOLaneAR, et al.APOE Expression and secretion are modulated by mitochondrial dysfunction. eLife2023; 12: e85779.
HarrisonDEStrongRSharpZD, et al.Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature2009; 460: 392–395.
27.
RoarkKMIfflandPH2nd. Rapamycin for longevity: the pros, the cons, and future perspectives. Front Aging2025; 6: 1628187.
28.
SharpZDStrongR. Rapamycin, the only drug that has been consistently demonstrated to increase mammalian longevity. An update. Exp Gerontol2023; 176: 112166.
29.
WilkinsonJEBurmeisterLBrooksSV, et al.Rapamycin slows aging in mice. Aging Cell2012; 11: 675–682.
30.
OddoS. The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed)2012; 4: 941–952.
31.
MillerSWTrimmerPAParkerWDJr, et al.Creation and characterization of mitochondrial DNA-depleted cell lines with “neuronal-like” properties. J Neurochem1996; 67: 1897–1907.
32.
BarrettMJAlonesVWangKX, et al.Mitochondria-derived oxidative stress induces a heat shock protein response. J Neurosci Res2004; 78: 420–429.
33.
ZhangDLiAMHuG, et al.PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. Cell Metab2023; 35: 517–534.e518.
34.
MautheMOrhonIRocchiC, et al.Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy2018; 14: 1435–1455.
35.
PanTRawalPWuY, et al.Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience2009; 164: 541–551.
36.
WangJLeeJLiemD, et al.HSPA5 Gene encoding Hsp70 chaperone BiP in the endoplasmic reticulum. Gene2017; 618: 14–23.
37.
FedeleAOProudCG. Chloroquine and bafilomycin A mimic lysosomal storage disorders and impair mTORC1 signalling. Biosci Rep2020; 40: BSR20200905.
38.
BednarskiELynchG. Selective suppression of cathepsin L results from elevations in lysosomal pH and is followed by proteolysis of tau protein. Neuroreport1998; 9: 2089–2094.
39.
JiaBXueYYanX, et al.Autophagy inhibitor chloroquine induces apoptosis of cholangiocarcinoma cells via endoplasmic reticulum stress. Oncol Lett2018; 16: 3509–3516.
40.
YinJGuLWangY, et al.Rapamycin improves palmitate-induced ER stress/NF κ B pathways associated with stimulating autophagy in adipocytes. Mediators Inflamm2015; 2015: 272313.
41.
FigueiredoVCMarkworthJFCameron-SmithD. Considerations on mTOR regulation at serine 2448: implications for muscle metabolism studies. Cell Mol Life Sci2017; 74: 2537–2545.
BrandMDNichollsDG. Assessing mitochondrial dysfunction in cells. Biochem J2011; 435: 297–312.
44.
LiuYSchubertDR. The specificity of neuroprotection by antioxidants. J Biomed Sci2009; 16: 98.
45.
KodihaMBańskiPStochajU. Interplay between MEK and PI3 kinase signaling regulates the subcellular localization of protein kinases ERK1/2 and Akt upon oxidative stress. FEBS Lett2009; 583: 1987–1993.
HallidayMRadfordHSekineY, et al.Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. Cell Death Dis2015; 6: e1672.
48.
ZachariMGanleyIG. The mammalian ULK1 complex and autophagy initiation. Essays Biochem2017; 61: 585–596.
49.
WongPMPuenteCGanleyIG, et al.The ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy2013; 9: 124–137.
50.
KimJKunduMViolletB, et al.AMPK And mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol2011; 13: 132–141.
51.
HarrisFMTesseurIBrechtWJ, et al.Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J Biol Chem2004; 279: 3862–3868.
52.
ChangSran MaTMirandaRD, et al.Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A2005; 102: 18694–18699.
53.
ChenHKJiZSDodsonSE, et al.Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem2011; 286: 5215–5221.
54.
HugginsCJMayekarMKMartinN, et al.C/EBPγ is a critical regulator of cellular stress response networks through heterodimerization with ATF4. Mol Cell Biol2015; 36: 693–713.
55.
CalkhovenCFMüllerCLeutzA. Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev2000; 14: 1920–1932.
56.
KalininAPZubkovaESMenshikovMY, et al.ISR Modulators in neurological diseases. Curr Neuropharmacol2025; 23: 1184–1214.
HandsSLProudCGWyttenbachA. mTOR's role in ageing: protein synthesis or autophagy?Aging (Albany NY)2009; 1: 586–597.
59.
SarbassovDDAliSMSabatiniDM. Growing roles for the mTOR pathway. Curr Opin Cell Biol2005; 17: 596–603.
60.
SilvaDFSelfridgeJELuJ, et al.Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum Mol Genet2013; 22: 3931–3946.
61.
SarbassovDDGuertinDAAliSM, et al.Phosphorylation and regulation of akt/PKB by the rictor-mTOR complex. Science2005; 307: 1098–1101.
62.
CorradettiMNGuanKL. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene2006; 25: 6347–6360.
63.
SarbassovDDAliSMKimDH, et al.Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol2004; 14: 1296–1302.
64.
SarbassovDDAliSMSenguptaS, et al.Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell2006; 22: 159–168.
65.
WizaCNascimentoEBOuwensDM. Role of PRAS40 in Akt and mTOR signaling in health and disease. Am J Physiol Endocrinol Metab2012; 302: E1453–E1460.
66.
YassineHNHugoCO'DonovanB, et al.APOE-targeted therapeutics for Alzheimer's disease. J Neurosci2025; 45: e1388252025.
67.
YamazakiYPainterMMBuG, et al.Apolipoprotein E as a therapeutic target in Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs2016; 30: 773–789.
68.
YamazakiYZhaoNCaulfieldTR, et al.Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol2019; 15: 501–518.
69.
LiZShueFZhaoN, et al.APOE2: Protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener2020; 15: 63.
70.
GonzalesMMGarbarinoVRKautzTF, et al.Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial. Commun Med (Lond)2025; 5: 189.
71.
SpilmanPPodlutskayaNHartMJ, et al.Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One2010; 5: e9979.
72.
LinALZhengWHalloranJJ, et al.Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J Cereb Blood Flow Metab2013; 33: 1412–1421.
73.
SuttonMASchumanEM. Dendritic protein synthesis, synaptic plasticity, and memory. Cell2006; 127: 49–58.
74.
SidrauskiCAcosta-AlvearDKhoutorskyA, et al.Pharmacological brake-release of mRNA translation enhances cognitive memory. eLife2013; 2: e00498.
75.
OliveiraMMLourencoMVLongoF, et al.Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease. Sci Signal2021; 14: eabc5429.
76.
ChangRCWongAKNgHK, et al.Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport2002; 13: 2429–2432.
77.
ZalocuskyKANajmRTaubesAL, et al.Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease. Nat Neurosci2021; 24: 786–798.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
